Parabilis Medicines, Inc. (PBLS)
40.11
+0.64
(+1.62%)
USD |
NASDAQ |
Sep 02, 16:00
40.01
-0.10
(-0.25%)
Pre-Market: 08:52
Parabilis Medicines Research and Development Expense (Annual) : 125.01M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 125.01M |
| Date | Value |
|---|---|
| December 31, 2024 | 100.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Moderna, Inc. | 2.917B |
| Kailera Therapeutics, Inc. | 109.11M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |
| Sangamo Therapeutics, Inc. | 112.67M |